Security Snapshot

Evommune, Inc. - Common Stock, par value $0.0001 per share (EVMN) Institutional Ownership

CUSIP: 30054Y107

13F Institutional Holders and Ownership History from Q4 2025 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

70

Shares (Excl. Options)

28.78MFull value: 28,776,369 · shares · 30 Sep 2026

Price

$8.26

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+208,106
Value change
-$28,261,969
Number of holders
70
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
36,329,552
SEC-reported price per share
$6.81
Insider filing price
$6.81
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • EVMN - Evommune, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 30054Y107.
  • 70 institutions reported positions in Q3 2026.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 104 to 70 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $462.18MFull value: $462,177,708 · USD · 30 Jun 2026
    to
    $237.7MFull value: $237,698,161 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 70 institutions filings for Q3 2026.

Open SEC evidence

Security key

30054Y107

13F reference period

Q3 2026

13F holders

70

13D/G owners

6

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
6
Security
EVMN
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
LSP 7 Cooperative UA 15% -6.2% $114,491,976 +$7,765,422 5,288,313 +7.3% LSP 7 Cooperatieve U.A. 12 Feb 2026
RA CAPITAL MANAGEMENT, L.P. 8.5% -12% $28,865,710 3,494,638 0% RA Capital Management, L.P. 06 Nov 2026
Pivotal bioVenture Partners Fund I, L.P. 11% $69,158,608 3,435,599 Nan Fung Group Holdings Limited 31 Dec 2025
Point72 Asset Management, L.P. 6.7% +28% $20,105,501 +$4,324,862 2,434,080 +27% Point72 Asset Management, L.P. 30 Sep 2026
Andera Partners 3.9% -35% $17,204,996 -$6,246,398 1,391,990 -27% Andera Partners 30 Jun 2026
PRICE T ROWE ASSOCIATES INC /MD/ 2.3% -62% $7,036,413 -$8,995,743 851,866 -56% T. Rowe Price Associates, Inc. 30 Sep 2026
As of 30 Sep 2026, 70 institutional investors reported holding
28.78MFull value: 28,776,369 · shares · 30 Sep 2026
shares of Evommune, Inc. - Common Stock, par value $0.0001 per share (EVMN). This represents 79% of the company’s total
36.33MFull value: 36,329,552 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
67%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
EQT Fund Management S.a r.l. 15% 5,288,313 4.6% $43,681,465
RA CAPITAL MANAGEMENT, L.P. 9.6% 3,494,638 0.29% $28,865,710
Point72 Asset Management, L.P. 6.7% 2,434,080 0.03% $20,105,501
Pivotal bioVenture Partners Investment Advisor LLC 5.3% 1,926,943 6.3% $15,916,549
Defilade Capital Management, L.P. 3.9% 1,430,573 2% $11,816,533
Vestal Point Capital, LP 3.4% 1,250,000 0.27% $10,325,000
BAKER BROS. ADVISORS LP 3.4% 1,234,794 0.05% $10,199,398
Kynam Capital Management, LP 3.3% 1,200,000 0.55% $9,912,000
VANGUARD CAPITAL MANAGEMENT LLC 2.8% 1,004,473 0% $8,296,947
Qube Research & Technologies Ltd 1.9% 684,713 0.01% $5,655,729
SILVERARC CAPITAL MANAGEMENT, LLC 1.6% 594,027 0.6% $4,906,663
GEODE CAPITAL MANAGEMENT, LLC 1.3% 467,271 0% $3,860,818
Velan Capital Investment Management LP 1.3% 456,255 3.6% $3,768,666
SPHERA FUNDS MANAGEMENT LTD. 1.1% 390,632 0.49% $3,226,620
GREAT POINT PARTNERS LLC 0.89% 325,000 0.7% $2,684,500
GOLDMAN SACHS GROUP INC 0.83% 301,400 0% $2,489,564
Trexquant Investment LP 0.78% 284,954 0.01% $2,353,720
STATE STREET CORP 0.74% 267,910 0% $2,212,937
TWO SIGMA INVESTMENTS, LP 0.72% 259,835 0% $2,146,237
RTW INVESTMENTS, LP 0.57% 208,071 0.02% $1,718,666
SummitTX Capital, L.P. 0.56% 201,714 0.04% $1,666,158
XTX Topco Ltd 0.46% 166,671 0.02% $1,376,702
ORBIMED ADVISORS LLC 0.44% 161,000 0.02% $1,329,860
Y-Intercept (Hong Kong) Ltd 0.44% 158,813 0.03% $1,311,795
VANGUARD FIDUCIARY TRUST CO 0.42% 152,823 0% $1,262,318

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
4
Headline period
Q3 2026
Rows shown
1-4 of 4
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 28,776,369 $237,698,161 -$28,261,969 $8.26 70
2026 Q2 34,570,369 $462,177,708 -$34,339,695 $13.29 104
2026 Q1 34,576,739 $793,406,919 +$167,246,545 $22.99 84
2025 Q4 27,200,904 $465,685,578 +$403,679,610 $17.12 59
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .